ArticleMolecular diagnosis & therapy2016
Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor.
Article in Molecular diagnosis & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application.Journal of surgical oncology · 2026Review
- Clinical Use of Liquid-Based Comprehensive Genomic Profiling in Gastrointestinal Stromal Tumors.Laboratory investigation; a journal of technical methods and pathology · 2025Article
- Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.International journal of molecular sciences · 2023Review
- Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).International journal of molecular sciences · 2023Article
- Plasma Sequencing for Patients with GIST-Limitations and Opportunities in an Academic Setting.Cancers · 2022Article
- Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies.Frontiers in oncology · 2022Article
- Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives.Cancers · 2021Review
- Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time?Current treatment options in oncology · 2021Review
- Progress in determining response to treatment in gastrointestinal stromal tumor.Expert review of anticancer therapy · 2020Review
- Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.BMC cancer · 2020Article
- The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids.Journal of Cancer · 2020Review
- Article
- Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors.Therapeutic advances in medical oncology · 2019Review
- A single digital droplet PCR assay to detect multipleOncotarget · 2018Article
- Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature.Oncotarget · 2017Article
- Gastrointestinal endoscopy in early diagnosis and treatment of gastrointestinal tumors.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAssessment of KIT/PDGFRA mutations is essential for therapeutic decision making in patients with gastrointestinal stromal tumor (GIST). Blood-derived circulating tumor DNA can provide molecular information representative of the tumor tissue.
methodsIn this study, primary tumors and matched presurgical blood samples were collected from 25 patients with localized gastric GIST, and the DNAs were analyzed for KIT and PDGFRA mutations using a next-generation sequencing platform.
resultsSequencing of the tumors identified mutations in KIT exon 11 in 18/25 cases (72 %). The mutations were detected in 13/18 (72 %) plasma samples from the patients harboring KIT mutation in the paired GIST tissue. Identical point mutations were found in three of the presurgical plasma samples, and insertion/deletions were detected as single-base substitutions in ten cases. No mutations were detected in plasma samples from the seven patients with KIT/PDGFRA wild-type GIST.
conclusionOur study demonstrates that primary KIT mutations can be detected in the presurgical plasma of patients with localized GIST; this would help clinicians reach proper diagnoses before surgery and assist them to make appropriate therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.